Company Overview of T2 Biosystems, Inc.
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. Its T2 Magnetic Resonance platform enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company offers T2Dx, a bench-top instrument for sepsis, Lyme disease, and other applications; T2Candida panel for identifying pathogens associated with sepsis; and T2MR Platform, a magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. It is also developing T2Stat, an integrated instrument that provi...
101 Hartwell Avenue
Lexington, MA 02421
Founded in 2006
Key Executives for T2 Biosystems, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $380.4K
Chief Financial Officer
Total Annual Compensation: $171.9K
Chief Operating Officer
Total Annual Compensation: $89.8K
Chief Medical Officer
Total Annual Compensation: $228.4K
Chief Scientific Officer
Total Annual Compensation: $274.3K
Compensation as of Fiscal Year 2014.
T2 Biosystems, Inc. Key Developments
T2 Biosystems, Inc. Announces the Results of Two Investigational Studies Highlighting the Capability of its T2 Magnetic Resonance Detector to Accurately and Rapidly Measure Hemostasis Parameters Directly in Whole Blood
Jun 23 15
T2 Biosystems, Inc. announced the results of two investigational studies highlighting the capability of its T2 Magnetic Resonance detector to accurately and rapidly measure hemostasis parameters directly in whole blood. In both studies, T2MR demonstrated strong correlation to a current standard of care, while doing so on a single instrument suitable for point of care testing, drug development, animal studies, and biomarker discovery. The results were presented at the International Society on Thrombosis and Haemostasis 2015 Congress in Toronto, Canada. T2MR Platelet Analysis Correlates with Light Transmission Aggregometry and Rapidly Reveals Unique Details of ADP-Mediated Platelet Activation in Whole Blood: The current standard of care for measuring platelet activation, an important factor in making therapeutic, surgical, and transfusion decisions, generally requires specialized laboratories and personnel, large volumes of blood and takes approximately three hours to obtain a result. In this study, T2MR detected the most clinically valuable platelet parameters to provide an assessment of platelet activity in just 20 minutes using low blood volumes while demonstrating 100% correlation to the current standard of care. Whole Blood Platelet Activity Measurements Multiplexed with Quantitative Fibrinogen, Clot Time and Fibrinolysis Measurements by T2MR: Currently, there is no single solution for rapidly measuring the four key measures of coagulation: clotting time, platelet function, fibrinogen and fibrinolysis. These measures together are critical for determining patient risk for clotting or bleeding. In this study, T2MR was shown to rapidly and accurately assess potential bleeding disorders through a single multiplex analysis of global hemostasis utilizing low blood volumes. In addition, T2MR generated robust signatures that have led to the discovery of novel biomarkers that may potentially have other important clinical applications.
T2 Biosystems, Inc. Announces Board Changes
Jun 22 15
On June 19, 2015, T2 Biosystems, Inc. received a written letter of resignation from Alan Crane stating that he resigned, effective immediately prior to the company's 2015 Annual Stockholder Meeting held on June 19, 2015, from his position as a Class I member of the Board of Directors of the company. Mr. Crane resigned from the Board to pursue other business opportunities and not as a result of any dispute or disagreement with the company or any member of its management. Mr. Crane served on the company's Compensation Committee prior to his resignation. Following Mr. Crane's resignation from the Board, the Compensation Committee is now comprised of the following members of the Board: Stanley Lapidus (Chairman) and Thomas Carella.
T2 Biosystems, Inc. Presents at BIO International Convention 2015, Jun-15-2015 through Jun-18-2015
Jun 11 15
T2 Biosystems, Inc. Presents at BIO International Convention 2015, Jun-15-2015 through Jun-18-2015. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Presentation Date & Speakers: Jun-17-2015, John P. McDonough, Chief Executive Officer, President and Director. Jun-18-2015, Thomas J. Lowery, Chief Scientific Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|